BioSpace News Archive

Galapagos NV(Euronext & Nasdaq: GLPG)reports topline results with GLPG3970 in three patientstudies.GLPG3970, the first product candidatefrom a broad portfolio of SIK inhibitor compounds, provides clinicaldatasupporting the role of SIK inhibition in inflammation.

Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups announced the launch of VIP Siblings, a new website and suite of materials created to celebrate and deepen support for siblings of adolescents living with rare and severe forms of epilepsy.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jennifer Cochran, Ph.D. to the Company’s Board of Directors.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2021 on Thursday, July 29, 2021, following the close of the market.

Integra LifeSciences Holding Corporation, a leading global medical technology company, announced its SurgiMend® Collagen Matrix for Soft Tissue Reconstruction has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company.

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 1/2 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).

Topcon Corporation, a leading provider of medical devices and software solutions for the global eye care community, announced that it has acquired VISIA Imaging S.r.l, an ophthalmic device manufacturer headquartered in Florence, Italy.

Microneedle drug delivery system is a novel drug delivery system method in which the drug is delivered in the systemic circulation with the use of needles.

Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilized hypochlorous acid products for a wide range of applications, including wound care, eye, oral and nasal care and dermatological conditions announced financial results for fiscal year 2021 and the fourth quarter ended March 31, 2021.

The cryopreservation equipment market is projected to reach US$ 11,255.02 million by 2028 from US$ 5,798.82 million in 2021; it is expected to grow at a CAGR of 9.9% from 2021 to 2028.